Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Third Rock Ventures
AddedFeb 13, 2024
UpdatedJul 11, 2026
Third Rock Ventures

Third Rock Ventures

Operating

Third Rock Ventures: A venture capital firm investing in life sciences and biotech in MA and CA.

Location
Boston, MA, US
Founded
2007
Firm
Compare
Portfolio
Employees
Website

Investments

Flare Therapeutics
Flare Therapeutics
Series C

Total Raised

$290M

Rounds

3

Series C$85MJune 2026
Series B$123MMarch 2023
Series A$82MMay 2021
Synnovation Therapeutics
Synnovation Therapeutics

Total Raised

$139M

Rounds

3

Series A$102MDecember 2023
Artbio
Artbio

Total Raised

$113M

Rounds

2

Series A$90MDecember 2023
Terremoto Biosciences
Terremoto Biosciences

Total Raised

$250M

Rounds

2

Series B$175MNovember 2023
Series A$75MMay 2022
Rapport Therapeutics
Rapport Therapeutics

Total Raised

$250M

Rounds

2

Series B$150MAugust 2023
Series A$100MMarch 2023
Septerna
Septerna

Total Raised

$250M

Rounds

2

Series B$150MJuly 2023
Series A$100MJanuary 2022
Casma Therapeutics
Casma Therapeutics

Total Raised

$154.9M

Rounds

4

Series C$46MNovember 2022
Series B$50MSeptember 2020
Moma Therapeutics
Moma Therapeutics

Total Raised

$236M

Rounds

2

Series B$150MMay 2022
Series A$86MApril 2020
Celsius Therapeutics
Celsius Therapeutics

Total Raised

$148M

Rounds

2

Series B$83MMarch 2022
Cedilla Therapeutics
Cedilla Therapeutics

Total Raised

$138.8M

Rounds

3

Series B$25MOctober 2021
Series B$57.6MOctober 2020
Asher Bio
Asher Bio

Total Raised

$163.2M

Rounds

3

Series B$108MSeptember 2021
Series A$55MMarch 2021
Abata Therapeutics
Abata Therapeutics

Total Raised

$95M

Rounds

1

Series A$95MJune 2021
Insitro
Insitro

Total Raised

$643M

Rounds

3

Series C$400MMarch 2021
Series B$143MMay 2020
Faze Medicines
Faze Medicines

Total Raised

$81M

Rounds

1

Series A$81MDecember 2020
Thrive Earlier Detection
Thrive Earlier Detection

Total Raised

$367M

Rounds

3

Series B$257MJuly 2020